TerminatedNot Applicable

DESolve® X-Pand Global Post Market Registry

Stopped: slow enrollment due to change in worldwide scaffold usage

Germany, Netherlands154 participantsStarted 2015-05-13

Plain-language summary

The X-Pand Registry is intended to facilitate analysis of acute \& long-term safety as well as treatment outcomes with DESolve in patients with CAD.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Minimal age 18 years
✓. Patient is willing/able to cooperate with study procedures and required follow up visits. Patient or legal representative has been informed \& agrees by signing EC approved written consent. Consent can occur before implantation of the DESolve scaffold (planned procedure) or within 30 days post implantation procedure for retrospective enrollment (unplanned procedure).
✓. Planned or unplanned DESolve scaffold implantation

TLF (Target Lesion Failure)

Timeframe: 12 months

Death

Timeframe: 12 months

CABG

Timeframe: 12 months

CD-TVR

Timeframe: 12 months

NCT IDNCT02453035

SponsorElixir Medical Corporation

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2017-03-31